Bortezomib in Combination with Physachenolide C Reduces the Tumorigenic Properties of KRAS^mut/P53^mut Lung Cancer Cells by Inhibiting c-FLIP.

ABSTRACT:

Background

Defects in apoptosis regulation are one of the classical features of cancer cells, often associated with more aggressiveness and failure to therapeutic options. We investigated the combinatorial antitumor effects of a natural product, physachenolide C (PCC) and bortezomib, in KRAS^mut/P53^mut lung cancer cells and xenograft mice models.

Methods

The in vitro anticancer effects of the bortezomib and PCC combination were investigated using cell viability, migration, and invasion assays in 344SQ, H23, and H358 cell lines. Furthermore, the effects of combination treatment on the critical parameters of cellular metabolism, including extracellular acidification rate (ECAR) and mitochondrial oxidative phosphorylation based on the oxygen consumption rat

SUBMITTER: Kanagasabai T 

PROVIDER: S-EPMC10854725 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature